MedTrace Logo

Sub-dissociative Dose Ketamine Dosing Study

NCT03714620 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2022-08-09

Study results available
· View outcomes & findings →

Summary

Goal is to determine if in adults presenting to the Emergency Department (ED) with moderate to severe acute pain, Ketamine administered at 0.15 mg/kg will provide similar pain relief to Ketamine administered at 0.3 mg/kg, with fewer adverse effects.

Conditions

  • Acute Pain

Interventions

DRUG

Ketamine

Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes

Sponsors & Collaborators

  • Loyola University

    lead OTHER

Principal Investigators

  • Shannon Lovett, MD · Loyola University Chicago, LUMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2019-09-17
Completion
2019-09-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03714620 on ClinicalTrials.gov